2026 ICD-10-CM Diagnosis Code T46.6X5SAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T46.6X5S is a billable ICD-10-CM diagnosis code for adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T46.6X5S.
Present on Admission (POA)Billing
T46.6X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acipimox adverse reaction
- Adverse reaction caused by atorvastatin
- Adverse reaction caused by cerivastatin
- Adverse reaction caused by fluvastatin
- Adverse reaction caused by lovastatin
- Adverse reaction caused by pitavastatin
- Adverse reaction caused by pravastatin
- Adverse reaction caused by rosuvastatin
- Adverse reaction caused by simvastatin
- Anion exchange resins adverse reaction
- Bezafibrate adverse reaction
- Cholestyramine adverse reaction
- Ciprofibrate adverse reaction
- Clofibrate adverse reaction
- Colestipol adverse reaction
- Complication of preventive medicine procedure
- Fenofibrate adverse reaction
- Fibric acid and/or fibric acid derivative adverse reaction
- Gemfibrozil adverse reaction
- Guar gum adverse reaction
- HMG COA reductase inhibitor adverse reaction
- Ion exchange resin adverse reaction
- Lipid-lowering drug adverse reaction
- Myalgia caused by statin
- Probucol adverse reaction
- Rhabdomyolysis due to statin
- Statin-induced myopathy
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Bezafibrate
an antilipemic agent that lowers cholesterol and triglycerides. it decreases low density lipoproteins and increases high density lipoproteins.Clofibrate
a fibric acid derivative used in the treatment of hyperlipoproteinemia type iii and severe hypertriglyceridemia. (from martindale, the extra pharmacopoeia, 30th ed, p986)Colestipol
highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. it may also may reduce triglyceride levels.Fenofibrate
an antilipemic agent which reduces both cholesterol and triglycerides in the blood.Gemfibrozil
a lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.Halofenate
an antihyperlipoproteinemic agent and uricosuric agent.Linoleic Acid
a doubly unsaturated fatty acid, occurring widely in plant glycosides. it is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (from stedman, 26th ed)Linoleic Acids
eighteen-carbon essential fatty acids that contain two double bonds.Linoleic Acids, Conjugated
a collective term for a group of around nine geometric and positional isomers of linoleic acid in which the trans/cis double bonds are conjugated, where double bonds alternate with single bonds.Linoleoyl-CoA Desaturase
an enzyme that catalyzes the syn-dehydrogenation of linoleol-coa gamma-linolenoyl-coa. it was formerly characterized as ec 1.14.99.25.Lovastatin
a fungal metabolite isolated from cultures of aspergillus terreus. the compound is a potent anticholesteremic agent. it inhibits 3-hydroxy-3-methylglutaryl coenzyme a reductase (hydroxymethylglutaryl coa reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. it also stimulates the production of low-density lipoprotein receptors in the liver.Oleic Acid
an unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. it is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (stedman, 26th ed)Oleic Acids
a group of fatty acids that contain 18 carbon atoms and a double bond at the omega 9 carbon.Ricinoleic Acids
eighteen carbon fatty acids that comprise the great majority of castor oil, which is from the seed of ricinus.Pravastatin
an antilipemic fungal metabolite isolated from cultures of nocardia autotrophica. it acts as a competitive inhibitor of hmg coa reductase (hydroxymethylglutaryl coa reductases).Probucol
a drug used to lower ldl and hdl cholesterol yet has little effect on serum-triglyceride or vldl cholesterol. (from martindale, the extra pharmacopoeia, 30th ed, p993).Safflower Oil
an oily liquid extracted from the seeds of the safflower, carthamus tinctorius. it is used as a dietary supplement in the management of hypercholesterolemia. it is used also in cooking, as a salad oil, and as a vehicle for medicines, paints, varnishes, etc. (dorland, 28th ed & random house unabridged dictionary, 2d ed)Simvastatin
a derivative of lovastatin and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase (hydroxymethylglutaryl coa reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. it may also interfere with steroid hormone production. due to the induction of hepatic ldl receptors, it increases breakdown of ldl cholesterol.Sitosterols
a family of sterols commonly found in plants and plant oils. alpha-, beta-, and gamma-isomers have been characterized.Triparanol
antilipemic agent with high ophthalmic toxicity. according to merck index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T46.6X5S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T46.6X5SOverview
Is T46.6X5S a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T46.6X5S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of antihyperlipidemic and antiarteriosclerotic drugs itself has resolved, not the original event.
What MS-DRG does T46.6X5S group to?
On inpatient claims, adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T46.6X5S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T46.6X5S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
